Last edition
News about Ingredients
Co-Diagnostics Inc, a molecular diagnostics company with a patented platform for developing molecular diagnostic tests, has received an Australian patent grant for its next-generation polymerase chain reaction (PCR) platform, reinforcing its intellectual property base supporting future manufacturing and commercialization.
Ingredients | 31/12/2025 | By Darshana
Boehringer Advances First-in-Class Triple-Agonist Peptide for Obesity and CRM Disorders
Boehringer Ingelheim has announced the advancement of BI 3034701, a long-acting, potential first-in-class triple-agonist peptide being developed for the treatment of obesity. The progress marks a key milestone in the company’s strategy to tackle the global burden of obesity and its interlinked cardiovascular, renal, and metabolic (CRM) complications.
Ingredients | 09/12/2025 | By Darshana | 121
Citius Oncology Launches Lymphir, a Novel FDA-Approved Therapy for Relapsed or Refractory CTCL
According to Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals, the launch of Lymphir marks a major milestone for the company. He highlighted its median time to response of 1.4 months, noting that the therapy may provide rapid relief from the severe and debilitating itching associated with CTCL.
Ingredients | 04/12/2025 | By Darshana
Zaynich milestone: First Indian-developed NCE accepted by US FDA
Wockhardt Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich.
Ingredients | 02/12/2025 | By Darshana | 138
Eisai completes FDA submission for weekly subcutaneous LEQEMBI autoinjector
Eisai has completed the rolling submission of its Supplemental Biologics License Application (sBLA) to the US Food and Drug Administration for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector formulation of lecanemab-irmb (LEQEMBI), following the FDA’s Fast Track designation.
Ingredients | 27/11/2025 | By Darshana
Lupin Manufacturing Solutions Commissions Dedicated Oncology Block at Vizag Facility
Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin, has commissioned a dedicated oncology manufacturing block at its Vizag facility in India.
Ingredients | 12/11/2025 | By Dineshwori | 159
Valiant Advanced Sciences Begins Commercial Operations at New Greenfield Facility in Gujarat
According to Valiant Advanced Sciences, the new plant is dedicated to the production of Acetic Anhydride, a key chemical in the Ketene and Diketene derivatives category, serving both domestic and international markets.
Ingredients | 07/11/2025 | By Dineshwori | 158
Cambridge Isotope Laboratories (CIL), a subsidiary of Otsuka Pharmaceutical (Japan), has launched ISOAPI-D, a unified brand of deuterated intermediates for active pharmaceutical ingredient (API) synthesis, at CPhI Frankfurt.
Ingredients | 29/10/2025 | By Dineshwori | 112
Genenta Science and Anemocyte expand collaboration to advance off-the-shelf LVV Plasmid DNA platform
Genenta Science, a pioneer in immuno-oncology, and Anemocyte, a leading provider of advanced therapy and nucleic acid solutions, have announced an expanded strategic collaboration focused on developing an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform.
Ingredients | 27/10/2025 | By Darshana | 142
AMSBIO Unveils New Range of Cytokines Tailored for Organoid and Stem Cell Studies
AMS Biotechnology (Amsbio) has introduced a new range of over 30 independently developed and manufactured organoid culture-related cytokines for researchers working with stem cells and induced pluripotent stem cells (iPSCs).
Ingredients | 14/10/2025 | By Dineshwori | 174
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy